Guardant Health reported Q1 2026 revenue growth of 48% year over year, driven by increases in both minimal residual disease (MRD) testing and broader oncology and screening activity. The company beat analysts’ expectations with $301.7 million total revenue for the quarter and raised its full-year guidance to $1.30 billion to $1.32 billion from $1.25 billion to $1.28 billion. Management attributed gains to higher oncology testing revenue and volumes, including 36% growth in oncology testing revenue and a 47% rise in oncology test volumes. Guardant also said Reveal MRD volumes more than doubled year over year during the quarter and noted that it has submitted data packages to CMS’s MolDx program in multiple cancer surveillance and monitoring areas. The company said Guardant360 Liquid volumes grew 30% year over year and that Guardant360 Tissue growth is supported by an upgrade to include whole-transcriptome RNA testing, which executives positioned as a volume catalyst by expanding the set of patients who can benefit from the assay.